Approval to expand the product matrix to include the 38 mm length taxus libert paclitaxel-eluting coronary stent system.  The device size will be marketed under the trade name taxus libert long paclitaxel-eluting coronary stent system (monorail and over-the-wire delivery systems), and is indicated for improving luminal diameter for the treatment of de novo lesions in native coronary arteries >=2.75 mm to <=4.00 mm in diameter in lesions <=34 mm in length.